ReviewChinese journal of cancer2013
Contemporary approach to diagnosis and classification of renal cell carcinoma with mixed histologic features.
Review in Chinese journal of cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- The intersection of histologies: navigating the complexity of a renal collision tumor.The Canadian journal of urology · 2025Article
- Data-Independent Acquisition Phosphoproteomics of Urinary Extracellular Vesicles Enables Renal Cell Carcinoma Grade Differentiation.Molecular & cellular proteomics : MCP · 2023Article
- The Regulating Effect of Autophagy-Related MiRNAs in Kidney, Bladder, and Prostate Cancer.Journal of oncology · 2021Review
- Hybrid oncocytic/chromophobe renal tumors are molecularly distinct from oncocytoma and chromophobe renal cell carcinoma.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Patterns of gene expression characterize T1 and T3 clear cell renal cell carcinoma subtypes.PloS one · 2019Article
- Effect of Everolimus on Heterogenous Renal Cancer Cells Populations Including Renal Cancer Stem Cells.Stem cell reviews and reports · 2018Article
- Diagnostic and prognostic biomarker potential of kallikrein family genes in different cancer types.Oncotarget · 2018Article
- Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.Chinese journal of cancer · 2018Article
- The Role of YB1 in Renal Cell Carcinoma Cell Adhesion.International journal of medical sciences · 2018Article
- Novel germline mutations in FLCN gene identified in two Chinese patients with Birt-Hogg-Dubé syndrome.Chinese journal of cancer · 2017Article
- Wilms' tumor in a 51-year-old patient: An extremely rare case and review of the literature.Molecular and clinical oncology · 2016Article
- Tim-3 expression represents dysfunctional tumor infiltrating T cells in renal cell carcinoma.World journal of urology · 2016Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal cell carcinoma (RCC) is an important contributor to cancer-specific mortality worldwide. Targeted agents that inhibit key subtype-specific signaling pathways have improved survival times and have recently become part of the standard of care for this disease. Accurately diagnosing and classifying RCC on the basis of tumor histology is thus critical. RCC has been traditionally divided into clear-cell and non-clear-cell categories, with papillary RCC forming the most common subtype of non-clear-cell RCC. Renal neoplasms with overlapping histologies, such as tumors with mixed clear-cell and papillary features and hybrid renal oncocytic tumors, are increasingly seen in contemporary practice and present a diagnostic challenge with important therapeutic implications. In this review, we discuss the histologic, immunohisto-chemical, cytogenetic, and clinicopathologic aspects of these differential diagnoses and illustrate how the classification of RCC has evolved to integrate both the tumor's microscopic appearance and its molecular fingerprint.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.